Bone Biologics (BBLG) Short Interest Ratio & Short Volume

Short interest is the volume of Bone Biologics shares that have been sold short but have not yet been covered or closed out. As of March 15th, investors have sold 76,500 shares of BBLG short. 14.34% of Bone Biologics' shares are currently sold short. Learn More on Bone Biologics' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 14.34% of Bone Biologics' floating shares are currently sold short.

Bone Biologics saw a drop in short interest in March. As of March 15th, there was short interest totaling 76,500 shares, a drop of 60.4% from the previous total of 193,300 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Bone Biologics currently has issued a total of 3,271,000 shares. Some of Bone Biologics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Bone Biologics currently has a public float of 533,600 shares.

14.34% of Bone Biologics' shares are currently sold short. Here is how the short interest of companies in the industry of "medical equipment" compare to Bone Biologics: Lyra Therapeutics, Inc. (3.85%), STRATA Skin Sciences, Inc. (0.09%), Inspira Technologies Oxy B.H.N. Ltd. (0.69%), NeuroMetrix, Inc. (0.10%), PAVmed Inc. (3.80%), Star Equity Holdings, Inc. (1.69%), Meihua International Medical Technologies Co., Ltd. (0.19%), Innovative Eyewear, Inc. (3.32%), Predictive Oncology Inc. (5.57%), Plus Therapeutics, Inc. (8.10%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($26.28 billion), iShares 20+ Year Treasury Bond ETF ($9.53 billion), MicroStrategy Incorporated ($8.50 billion), Apollo Global Management, Inc. ($4.86 billion), Super Micro Computer, Inc. ($4.85 billion), Charter Communications, Inc. ($4.28 billion), Capital One Financial Co. ($4.08 billion), AppLovin Co. ($3.82 billion), Canadian Natural Resources Limited ($3.78 billion), and Schlumberger Limited ($2.87 billion). View all of the most shorted stocks.

Short selling BBLG is an investing strategy that aims to generate trading profit from Bone Biologics as its price is falling. BBLG shares are trading down $0.02 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Bone Biologics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of BBLG, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including BBLG, twice per month. The most recent reporting period available is March, 15 2025.